Additionally, ERBB2 represents a therapeutic target mutation in NSCLC patients, and ERBB2-directed therapies can be effective in managing disease progression in individuals with metastatic ERBB2-mutated NSCLC [46]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.